We aimed to focus on PON1 rs705379, rs854560, and rs662 SNVs, as well as serum PON1 activity being assessed by catalytic efficiency for paraoxon hydrolysis (paraoxonase activity), concerning dyslipidaemia and atherosclerosis-related cardiovascular complications (coronary heart disease—CHD, type 1 myocardial infarction—MI, ischemic cerebral stroke—ICS) and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The gene discussed is PON1; the disease is coronary artery disorder.